Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Mary Anne Heino Sells 26,066 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director now directly owns 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mary Anne Heino also recently made the following trade(s):

• On Thursday, March 13th, Mary Anne Heino sold 2 shares of Lantheus stock. The shares were sold at an average price of $100.13, for a total transaction of $200.26.

Lantheus Stock Up 2.5%

NASDAQ:LNTH opened at $79.63 on Thursday. The company has a fifty day moving average of $90.93 and a 200 day moving average of $91.63. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89. The firm has a market capitalization of $5.51 billion, a P/E ratio of 13.25 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.69 earnings per share. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on LNTH shares. Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $132.67.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its position in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its position in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after buying an additional 2,361,000 shares during the period. Westfield Capital Management Co. LP boosted its stake in Lantheus by 2.2% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after purchasing an additional 34,052 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Lantheus by 2.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after purchasing an additional 31,454 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.